Neuvivo, a US-based, private late-clinical stage company developing an effective treatment for ALS and other neurodegenerative diseases, announced on Monday that it has added Peter Barton Hutt as advisor.

Hutt has served as senior counsel in the Washington, DC law firm of Covington & Burling LLP, specialising in Food and Drug Law. He has also served as chief counsel for the FDA. He has been a member of the National Academy of Medicine and a consultant to President Obama's Council of Advisors on Science and Technology. He has also served as a member of the National Committee to Review Current Procedures for Approval of New Drugs for Cancer and AIDS and on five Office of Technology Assessment advisory panels. He is also a member of the FDA Science Review Subcommittee. He has taught a full course on Food and Drug Law at Harvard Law School and is the lead co-author of the text used to teach Food and Drug Law at law schools throughout the country.

Ari Azhir, PhD, Neuvivo founder and CEO, said, 'Peter's background with the FDA and his expertise in regulatory matters is unparalleled. We are pleased to formally welcome him to Neuvivo. His excellent counsel and straightforward approach are valued, and we look forward to working together to make NP001 treatment broadly available to ALS patients as soon as possible.'